All Clinical Trials and Research Listed with MSRA Clinical Trials Network

Date Added

Description

More Information

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.

Physical Activity and Fatigue in Early Multiple Sclerosis (MS) (BEGIN)

The purpose of this observational study is to obtain a survey on physical activity in patients who for the first time have experienced symptoms which indicate a high risk for developing multiple sclerosis (MS) and in patients with recently diagnosed MS, and to obtain information on factors potentially influencing the patients' level of activity.

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis (SONIC)

A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis

The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor

The incidence of tremor in Multiple Sclerosis (MS) has been estimated to affect up to 2/3rds of patients. Over half of the tremors involve the upper limb and frequently lead to further disability. Medical treatment of MS tremor is generally unrewarding, although carbamazepine, clonazepam, glutethimide, hyoscine, isoniazid, ondansetron, primidone, and tetrahydrocannabinol have been reported to have some beneficial effect but published evidence of effectiveness is very limited. The investigators' experience to date suggests that many of the upper limb tremors may potentially be responsive to Botulinum toxin injection therapy.

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

This observational multicentric study is planned to assess the tolerability of Rebif New Formulation in an Australian clinical setting by the incidence of injection site reactions (ISRs). The study will allow the comparison of tolerability data with historical data for both Rebif New and classic formulations, and will do so by using the same pre- specified preferred terms of treatment emergent adverse events as done in historical studies. In addition, the study will analyse whether interaction(s) with a nurse impacts tolerability and the impact of Rebif New Formulation on the patient's Quality of Life.

ACT-128800 in Relapsing-remitting Multiple Sclerosis

This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.

Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis

The existing scientific and clinical experience with DAC HYP supports its further investigation in the management of multiple sclerosis (MS). This study is being conducted to determine the superiority of DAC HYP compared to IFN β-1a in preventing MS relapse in subjects with relapsing remitting MS (RRMS) when DAC HYP 150mg is administered SC once every 4 weeks for 96 to 144 weeks as compared to a 30mg IM injection of Interferon β1a once weekly for 96 to 144 weeks.

Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis

SB-683699 is an oral medication that is thought to reduce the number of active white blood cells entering the brain; these white blood cells are part of the disease process for MS. This study will look at whether different doses of SB-683699 are effective and safe in patients with relapsing remitting MS.

Measuring the effect of prolonged walking on balance, mobility and falls risk

MS Research Australia is funding a new study investigating the effect of prolonged walking on balance, mobility and falls risk in People with MS. Fatigue appears to be the greatest limitation to walking ability in People with MS, with lower limb weakness worsening with increasing walking distances. However, the correct combination of exercises and/or simple orthotics may help reduce the effects of fatigue on mobility while also reducing the risk of falls in People with MS. The study requires 40 participants living in the Adelaide (SA) area diagnosed with MS and living with mild to moderate mobility difficulty.

For more information about participating in the trial contact James McLoughlin by email.

Cognitive, behavioural and social skills in childhood-onset multiple sclerosis and childhood demyelination.

Due to technological advances and increased awareness, the numbers of children are being diagnosed with multiple sclerosis (MS) are steadily increasing.  There are also a significant percentage of adults with MS reporting symptom onset in childhood.   Adults with MS commonly experience difficulties in cognition, behaviour and social functioning, however, little is known about how childhood MS affects these skills.

Children aged between 6 and 16 years will be followed for two years from the time of diagnosis, to identify any patterns of difficulty, changes over time, and to establish support needs.  This study will measure the impact of childhood MS and demyelination on family, social, cognitive and academic skills.  These skills will be measured using several neuropsychological tests and questionnaires.  The findings from this study will help to provide the best treatment and management of affected children in the future.

A Prospective, Parallel Group, Non-Randomised Open-Label Observational Study Comparing Copaxone® With Interferons In Patients With Confirmed Multiple Sclerosis

The Australian MS Longitudinal Study

The Australian MS Longitudinal Study (AMSLS) is critical to understanding the full effects of MS on Australian society, including the individual and overall community cost. The data from the AMSLS provides a regularly updated evidence base for a number of stakeholders including health professionals, scientific and applied scientists and a specialist workforce servicing the MS community in an effort to improve understanding of MS and service delivery. Any Australian resident diagnosed with MS after June 2002 is eligible to join the Study. For more information about the AMSLS and how to participate visit the MSRA website.

Teenagers’ adjustment to their parent’s MS

Researchers at the University of Southampton (UK) are carrying out an anonymous research survey to help us understand factors which may help adolescents adjust to their parents’ MS and those made adjustment more difficult. Teenagers (13-18 years old) are asked to complete an online survey. The completion of the survey will take approximately 15 minutes.  If you are interested please read the attached information sheets or contact Angeliki Bogosian

To fill in the survey please read the attached information sheets and follow the link at the bottom of each page.

Information Sheet for Parents

Information Sheet for Teenagers

04/2010

A study exploring the preliminary safety, tolerability and pharmacokinetics of GSK1223249 administered by to patients with relapsing forms of MS not on disease modifying therapy. 

Download

2009

A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis

View

2009

An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis.

View

2009

An examination of prospective memory in MS, employment difficulties, and early departure from work

View